Form 4: Leap Therapeutics Executive Settles Restricted Stock Units, Adjusts Holdings

Christine Granfield, VP at Leap Therapeutics, settled restricted stock units on March 28, 2025, resulting in adjustments to her beneficial ownership of common stock.

Summary

• Christine Granfield, VP, Head of Regulatory Affairs/Quality at Leap Therapeutics, settled 22,500 Restricted Stock Units (RSUs) on March 28, 2025.
• The RSUs, granted on January 31, 2022, were settled on a net issue basis.
• Leap Therapeutics issued 15,896 shares to Granfield and withheld 6,604 shares to cover tax obligations.
• The share numbers reflect a 10-for-1 reverse stock split that occurred on June 20, 2023.
• Following the transaction, Granfield directly owns 15,896 shares of common stock.
• The settlement of the RSUs was deferred by the Compensation Committee until March 28, 2025, due to potential insider trading policy restrictions on the vesting date.

Sentiment

Score: 5

Explanation: This is a routine regulatory filing related to executive compensation. It doesn't inherently indicate positive or negative sentiment, but rather provides factual information about stock transactions.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track changes in ownership and potential alignment of interests.

Stakeholder Impact

• The settlement of RSUs impacts shareholders by slightly increasing the number of outstanding shares.
• The executive benefits from the compensation, aligning their interests with the company's performance.

Key Dates

Keywords

Restricted Stock Units, RSU, Form 4, Beneficial Ownership, Leap Therapeutics, LPTX, Insider Trading, Reverse Stock Split, Stock Settlement, Executive Compensation